The RTP site shared by the HIV-1 Tat protein and the 11S regulator subunit alpha is crucial for their effects on proteasome function including antigen processing
- PMID:12419264
- DOI: 10.1016/s0022-2836(02)00998-1
The RTP site shared by the HIV-1 Tat protein and the 11S regulator subunit alpha is crucial for their effects on proteasome function including antigen processing
Abstract
The human immunodeficiency virus-1 Tat protein inhibits the peptidase activity of the 20S proteasome and competes with the 11S regulator/PA28 for binding to the 20S proteasome. Structural comparison revealed a common site in the Tat protein and the 11S regulator alpha-subunit (REGalpha) called the REG/Tat-proteasome-binding (RTP) site. Kinetic assays found amino acid residues Lys51, Arg52 and Asp67 forming the RTP site of Tat to be responsible for the effects on proteasomes in vitro. The RTP site identified in REGalpha consists of the residues Glu235, Lys236 and Lys239. Mutation of the REGalpha amino acid residues Glu235 and Lys236 to Ala resulted in an REGalpha mutant that lost the ability to activate the 20S proteasome even though it still forms complexes with REGbeta and binds to the 20S proteasome. The REGalpha RTP site is needed to enhance the presentation of a cytomegalovirus pp89 protein-derived epitope by MHC class I molecules in mouse fibroblasts. Cell experiments demonstrate that the Tat amino acid residues 37-72 are necessary for the interaction of the viral protein with proteasomes in vivo. Full-length Tat and the Tat peptide 37-72 suppressed 11S regulator-mediated presentation of the pp89 epitope. In contrast, the Tat peptide 37-72 with mutations of amino acid residues Lys51, Arg52 and Asp67 to Ala was not able to reduce antigen presentation.
Similar articles
- Structure of the proteasome activator REGalpha (PA28alpha).Knowlton JR, Johnston SC, Whitby FG, Realini C, Zhang Z, Rechsteiner M, Hill CP.Knowlton JR, et al.Nature. 1997 Dec 11;390(6660):639-43. doi: 10.1038/37670.Nature. 1997.PMID:9403698
- Identification of an activation region in the proteasome activator REGalpha.Zhang Z, Clawson A, Realini C, Jensen CC, Knowlton JR, Hill CP, Rechsteiner M.Zhang Z, et al.Proc Natl Acad Sci U S A. 1998 Mar 17;95(6):2807-11. doi: 10.1073/pnas.95.6.2807.Proc Natl Acad Sci U S A. 1998.PMID:9501171Free PMC article.
- The proteasome activator 11 S REG or PA28: chimeras implicate carboxyl-terminal sequences in oligomerization and proteasome binding but not in the activation of specific proteasome catalytic subunits.Li J, Gao X, Joss L, Rechsteiner M.Li J, et al.J Mol Biol. 2000 Jun 9;299(3):641-54. doi: 10.1006/jmbi.2000.3800.J Mol Biol. 2000.PMID:10835274
- The proteasome activator 11 S REG (PA28) and class I antigen presentation.Rechsteiner M, Realini C, Ustrell V.Rechsteiner M, et al.Biochem J. 2000 Jan 1;345 Pt 1(Pt 1):1-15.Biochem J. 2000.PMID:10600633Free PMC article.Review.
- Structural and functional properties of proteasome activator PA28.Kuehn L, Dahlmann B.Kuehn L, et al.Mol Biol Rep. 1997 Mar;24(1-2):89-93. doi: 10.1023/a:1006897801858.Mol Biol Rep. 1997.PMID:9228287Review.
Cited by
- Host cell gene expression during human immunodeficiency virus type 1 latency and reactivation and effects of targeting genes that are differentially expressed in viral latency.Krishnan V, Zeichner SL.Krishnan V, et al.J Virol. 2004 Sep;78(17):9458-73. doi: 10.1128/JVI.78.17.9458-9473.2004.J Virol. 2004.PMID:15308739Free PMC article.
- Feline immunodeficiency virus OrfA alters gene expression of splicing factors and proteasome-ubiquitination proteins.Sundstrom M, Chatterji U, Schaffer L, de Rozières S, Elder JH.Sundstrom M, et al.Virology. 2008 Feb 20;371(2):394-404. doi: 10.1016/j.virol.2007.09.039. Epub 2007 Oct 25.Virology. 2008.PMID:17963812Free PMC article.
- Race to arsenal COVID-19 therapeutics: Current alarming status and future directions.Dubey AK, Singh A, Prakash S, Kumar M, Singh AK.Dubey AK, et al.Chem Biol Interact. 2020 Dec 1;332:109298. doi: 10.1016/j.cbi.2020.109298. Epub 2020 Oct 27.Chem Biol Interact. 2020.PMID:33121920Free PMC article.Review.
- The immunoproteasome and viral infection: a complex regulator of inflammation.McCarthy MK, Weinberg JB.McCarthy MK, et al.Front Microbiol. 2015 Jan 29;6:21. doi: 10.3389/fmicb.2015.00021. eCollection 2015.Front Microbiol. 2015.PMID:25688236Free PMC article.Review.
- New Peptide-Based Pharmacophore Activates 20S Proteasome.Osmulski PA, Karpowicz P, Jankowska E, Bohmann J, Pickering AM, Gaczyńska M.Osmulski PA, et al.Molecules. 2020 Mar 22;25(6):1439. doi: 10.3390/molecules25061439.Molecules. 2020.PMID:32235805Free PMC article.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous